Founded in March 2010, Asieris Pharmaceuticals is a global biopharmaceutical company built around unmet needs in genitourinary tumors and women’s health. Its distinctive focus is turning clinical research into accessible diagnosis and treatment, including the fertility-preserving therapy CEVIRA® for cervical precancerous lesions. The company operates R&D centers in Shanghai and the United States and became a Shanghai STAR Market-listed company in 2022.